Massachusetts Financial Services Co. MA Sells 20,617 Shares of Stryker Corporation $SYK

Key Points

• Massachusetts Financial Services Co. reduced its Stryker stake by 9.5%, selling 20,617 shares and retaining 195,835 shares worth approximately $67.8 million. Institutional investors collectively own 77.09% of the company.
• Stryker reported quarterly earnings of $3.69 per share, exceeding estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company issued FY 2026 EPS guidance of $14.95–$15.10.
• The company declared a quarterly dividend of $0.88, equal to an annualized $3.52 and a 1.0% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $386.28, despite recent insider share sales.

Massachusetts Financial Services Co. MA lessened its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 9.5% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 195,835 shares of the medical technology company's stock after selling 20,617 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.05% of Stryker worth $67,841,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Brighton Jones LLC raised its stake in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. bought a new position in Stryker during the second quarter valued at about $205,000. Marshall Wace LLP grew its position in Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company's stock valued at $2,255,000 after buying an additional 77,831 shares during the period. Nebula Research & Development LLC purchased a new stake in Stryker during the second quarter worth about $219,000. Finally, HUB Investment Partners LLC purchased a new stake in Stryker during the second quarter worth about $253,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, VP Robert S. Fletcher sold 4,544 shares of the firm's stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company's stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company's stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 4.60% of the company's stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $338.80 on Friday. The firm has a market capitalization of $129.95 billion, a PE ratio of 35.11, a P/E/G ratio of 2.17 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $324.61 and a two-hundred day moving average price of $333.57. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker's payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SYK. Citigroup reiterated a "buy" rating on shares of Stryker in a research note on Thursday. Robert W. Baird set a $385.00 price target on shares of Stryker in a research note on Friday, May 1st. BMO Capital Markets assumed coverage on shares of Stryker in a report on Wednesday, July 8th. They issued an "outperform" rating and a $369.00 price target on the stock. Piper Sandler dropped their price objective on Stryker from $420.00 to $390.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and a consensus target price of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source